Paediatric Cushing Disease: one patient's path to cure

The authors have nothing to disclose

Methods


G. Yordanova¹, V. lotova¹, E. Zheleva¹, C. Bachvarov¹, Y. Bocheva¹, S. Galcheva¹, Y. Enchev¹, K. Ivanov¹, N. Kolev¹, A. Tonev¹, H.L. Storr²

¹ UMHAT St. Marina, Varna, Bulgaria - Departments of Paediatrics and Medical Genetics, Imaging Diagnostics, Clinical Laboratory, Neurosurgery, General surgery. ² Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University London, London, UK

Objectives

History:

- 15 years old boy, diagnosed with Cushing's syndrome elsewhere
 - Initial signs and symptoms ≥ 2 yrs
 - Weight gain, growth arrest, skin changes, emotional lability, poor memory for recent events, eye problems
- Numerous inconclusive investigations for 6 mo Metformin therapy
- TSS unsuccessful (*no further treatment*)
- Presented 2 mo after TSS with escalating deterioration



Investigations: proved CD and localised hypophyseal corticotroph adenoma (Tables 1 & 2)

- Cortisol morning and midnight values, disturbed circadian rhythm
- Coupled plasma ACTH/cortisol inappropriately elevated
- UFC increased
- Overnight Dexamethasone suppression test (8 mg)
 - Cortisol (88.2%) and ACTH (90.5%) suppression >85%
- IPSS– basal ACTH ratio central/periphery >2/1 and left/right >1.5 - First time in the country

Physical examination:

- Weight 71.0 kg (SDS 1.25), height 148.1 cm, (H SDS -2.67, TH SDS -1.16), BMI 32.37 kg/m2 (SDS 2.96)
- Central obesity, "moon" face, buffalo hump
- Skin changes: acne, striae, hypertrichosis, bruises, flush, acanthosis
- Eye changes: discrete exophthalmos
- Pubertal: Tanner stage IV, TV 15 ml
- BP 115/89 mmHg, HR 84/min

- MRI of the pituitary region no adenoma found
- Pituitary function tests: partial gonadotrophin deficiency, low IGF-1
- Other:

 total and LDL cholesterol, no bone loss on DEXA

Management:

- Oral Ketoconazole (2x200mg) + planned for a second TSS
- Liver toxicity after 3 weeks on Ketoconazole and deterioration, related to the hypercortisolaemia
 - increased BP, hypokalemia and tendency towards hypernatremia, incipient heart decompensation
- **Decision for bilateral adrenalectomy (BA), due to the rapid health decline -** *lack of other oral adrenolytics in the country*

Table 2. IPSS				
Basal investigation	AC	Cortisol		
	right	left	peripheral	peripheral
Sinus petrosus inferior	46.7	183	39	520.7
V. jugularis int. supp.	48.5	105	44.1	513.9
V. jugularis int. inf	50.4	53	32.2	
Central/periphery ratio		4.7/1		
Lateralisation ACTH at S. petr. Inf. L/R		3.4/1		

Table 1. Hormonal investigations - presentation and follow-up (FU) - 6/9 months

Name	Presentation	FU 6 mo	FU 9 mo	Ref. range	Unit
Cortisol 00:00	601.94 (awake)	*on HC	*on HC	<50	nmol/l
Cortisol 08:00	977.5	255.9	48.04	50-550	nmol/l
ACTH	117.0	228	572	<46	pg/ml
UFC	1012.0	233.8	320.5	55.5-286	mkg/24h
IGF	159.0	193	595	237-996	ng/ml
LH	0.52	3.0	2.73	0.5-5.3	mIU/ml
FSH	4.0	4.0	4.34	0.3-8.2	mIU/ml
Testosteron	4.3	10.1	11.9	2.95-41.66	nmol/l
TSH	1.6	1.3	2.65	0.4-4	ulU/ml
FT4	14.4	13.8	13	10.3-24	pmol/l
Prolactin	72.7	89.3	92.4	53-360	ulU/ml

Results

Preparation for the BA:

- Preoperatively treated with i.v. Etomidate
- 24 hours prior BA in block-replace regimen (Methylprednisolone, when desired Cortisol levels of 100-200 nmol/l reached)
- No previous experience in the country

Laparoscopic BA

Postoperatively

- Hydrocortisone, Fludrocortisone and antihypertensives
- Uneventful postoperative period

FU at 6 months

- Weight reduction -8 kg (SDS 0.17)
- No catch-up growth (1 cm/6 mo, SDS -2.79)
- Advancing pubertal development (TV 20 ml)
- BP normalised
- Overcoming depression and anxiety
- GH deficiency
 - ITT and GT GH peak <10ng/ml (5.9 and 8.44 respectively)
 - BA 14 yr 10 mo
 - Started GH therapy (1.5 mg/day)

FU at 9 months

Catch-up on GH (3 cm/3 mo)



First weeks after the BA

- Elevated BP
- Swelling of the legs
- Anxiety attacks

- Two more anxiety attacks, blurred vision (left)
- Further levated ACTH
 - no signs of Nelson`s syndrome (MRI no change, no hyperpigmentation)
- Normal TSH, gonadotrophins and testosterone

References

Conclusions

Treatment of paediatric CD and its related complications is complex. Many factors can change the therapeutic course, including the lack of medications and experience in smaller centers. Multidisciplinary approach and collaboration with experts in the field are crucial for a successful outcome.

Storr HL, Savage MO. Management of endocrine disease: Paediatric Cushing's disease. Eur J Endocrinol. 2015; Oldfield EH et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991; Barber TM et al.. Nelson's syndrome. Eur J Endocrinol. 2010; Davies JH et al. Final Adult Height and Body Mass index after Cure of Paediatric Cushing's Disease. Clinical Endocrinology. 2005; CDC Growth charts: Stature for age and height for age percentiles, 2000.

